Float Short %

18.62

Margin Of Safety %

Put/Call OI Ratio

0.23

EPS Next Q Diff

0.08

EPS Last/This Y

2.21

EPS This/Next Y

0.1

Price

16.48

Target Price

35.17

Analyst Recom

1.14

Performance Q

3.1

Relative Volume

0.6

Beta

0.09

Ticker: QURE

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-08-15	QURE	16.19	0.24	0.79	69371
2025-08-18	QURE	15.68	0.19	0.49	49762
2025-08-19	QURE	15.34	0.20	0.06	49952
2025-08-20	QURE	15.49	0.20	0.22	49972
2025-08-21	QURE	15.47	0.20	0.31	51527
2025-08-22	QURE	15.68	0.20	2.95	53039
2025-08-25	QURE	15.56	0.19	1.18	53344
2025-08-26	QURE	15.82	0.21	0.79	54455
2025-08-27	QURE	15.78	0.23	1.60	56664
2025-08-28	QURE	16.26	0.24	1.45	59239
2025-08-29	QURE	16.34	0.25	0.16	59960
2025-09-02	QURE	17	0.25	0.05	59951
2025-09-03	QURE	17.37	0.22	0.53	68517
2025-09-04	QURE	17.73	0.24	0.11	68926
2025-09-05	QURE	18.03	0.24	0.02	69467
2025-09-08	QURE	17.44	0.23	0.58	71604
2025-09-09	QURE	17.49	0.24	0.36	72406
2025-09-10	QURE	17.48	0.24	0.18	72712
2025-09-11	QURE	16.94	0.22	1.76	77003
2025-09-12	QURE	16.48	0.23	0.43	77766
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-08-15	QURE	16.19	8.8	8.1	-2.69
2025-08-18	QURE	15.67	7.1	19.0	-2.76
2025-08-19	QURE	15.33	7.1	17.0	-2.76
2025-08-20	QURE	15.49	7.1	11.0	-2.76
2025-08-21	QURE	15.56	7.1	12.1	-2.76
2025-08-22	QURE	15.69	7.1	11.2	-2.76
2025-08-25	QURE	15.56	7.1	14.7	-2.76
2025-08-26	QURE	15.79	7.1	10.0	-2.76
2025-08-27	QURE	15.75	7.1	13.5	-2.76
2025-08-28	QURE	16.26	7.1	6.9	-2.76
2025-08-29	QURE	16.34	7.1	12.1	-2.76
2025-09-02	QURE	17.01	7.1	5.4	-2.72
2025-09-03	QURE	17.39	7.1	-7.0	-2.72
2025-09-04	QURE	17.71	7.1	-6.3	-2.72
2025-09-05	QURE	17.95	7.4	-4.8	-2.71
2025-09-08	QURE	17.43	7.4	3.5	-2.71
2025-09-09	QURE	17.48	7.4	-3.0	-2.71
2025-09-10	QURE	17.49	7.4	-2.0	-2.71
2025-09-11	QURE	16.94	7.4	3.8	-2.71
2025-09-12	QURE	16.48	7.4	3.0	-2.71
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-08-15	QURE	-2.29	26.93	18.89
2025-08-18	QURE	-2.29	40.34	19.32
2025-08-19	QURE	-1.89	40.34	19.32
2025-08-20	QURE	-1.89	40.34	19.32
2025-08-21	QURE	-1.89	40.34	19.32
2025-08-22	QURE	-1.89	40.34	19.32
2025-08-25	QURE	-1.89	11.15	19.32
2025-08-26	QURE	-1.89	11.15	19.32
2025-08-27	QURE	-1.89	11.15	19.99
2025-08-28	QURE	-1.10	11.15	19.99
2025-08-29	QURE	-1.10	11.15	19.99
2025-09-02	QURE	-1.10	10.80	19.99
2025-09-03	QURE	-1.10	10.80	19.99
2025-09-04	QURE	-1.10	10.80	19.99
2025-09-05	QURE	-1.10	10.80	19.99
2025-09-08	QURE	-0.35	10.76	19.99
2025-09-09	QURE	-0.35	10.76	19.99
2025-09-10	QURE	-0.35	10.76	19.99
2025-09-11	QURE	-0.35	10.76	18.62
2025-09-12	QURE	-0.35	10.76	18.62
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.69

Avg. EPS Est. Current Quarter

-0.77

Avg. EPS Est. Next Quarter

-0.61

Insider Transactions

-0.35

Institutional Transactions

10.76

Beta

0.09

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

68.4

Max Drawdown 5-Year %

-92.5

Target Price

35.17

P/E

Forward P/E

PEG

P/S

63.07

P/B

P/Free Cash Flow

EPS

-3.92

Average EPS Est. Cur. Y

-2.71

EPS Next Y. (Est.)

-2.61

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-1387.98

Relative Volume

0.6

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

0.01

EBIT Estimation

uniQure N.V.

Sector: Healthcare

Industry: Biotechnology

Employees: 209

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

stock quote shares QURE – uniQure N.V. Stock Price stock today

news today QURE – uniQure N.V. stock forecast ,stock prediction 2023 2024 2025

marketwatch QURE – uniQure N.V. yahoo finance google finance

stock history QURE – uniQure N.V. invest stock market

stock prices QURE premarket after hours

ticker QURE fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: QURE

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y